Literature DB >> 9062503

Omeprazole: calcitonin stimulation test for the diagnosis follow-up and family screening in medullary thyroid carcinoma.

M F Erdoğan1, S Güllü, N Başkal, A R Uysal, N Kamel, G Erdoğan.   

Abstract

Medullary thyroid carcinoma (MTC) occurs sporadically but may also be inherited as part of the multiple endocrine neoplasia (MEN) type 2 syndrome. Screening of the patients and first degree relatives annually with basal and provocative tests for serum immunoreactive calcitonin (CT) levels is essential and enables potentially curative disease. Pentagastrin and calcium are the usual provocative agents used worldwide. We used endogenous gastrin (GT) release achieved by omeprazole, 20 mg b.i.d., to stimulate CT in 9 MTC, in 3 MEN 2A family members, and in 50 healthy control subjects. A steady and significant increase both in GT and CT levels was achieved in 9 MTC patients and 3 of the 14 family members tested, whereas in healthy controls the CT increase stimulated by GT was insignificant. Preliminary results showed that this new, safe, cheap, and outpatient-basis test can be used in MTC diagnosis, follow-up, and screening.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062503     DOI: 10.1210/jcem.82.3.3797

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Long-term effects of elevated gastrin levels on calcitonin secretion.

Authors:  M F Erdogan; A Gursoy; M Kulaksizoglu
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  Editorial : Neuroendocrine neoplasms.

Authors:  Christian A Koch; Stephan Petersenn
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

3.  Stimulated calcitonin cut-offs by different tests.

Authors:  Laura Fugazzola
Journal:  Eur Thyroid J       Date:  2013-01-16

Review 4.  Drug therapy alternatives in the treatment of thyroid cancer.

Authors:  M J O'Doherty; A J Coakley
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

5.  Hypercalcitoninemia in thyroid conditions other than medullary thyroid carcinoma: a comparative analysis of calcium and pentagastrin stimulation of serum calcitonin.

Authors:  Kerstin Lorenz; Malik Elwerr; Andreas Machens; Mohammed Abuazab; Hans-Jürgen Holzhausen; Henning Dralle
Journal:  Langenbecks Arch Surg       Date:  2013-02-14       Impact factor: 3.445

6.  Calcitonin stimulation tests for the early diagnosis and follow-up of patients with C cell disease: a descriptive analysis.

Authors:  I Vainas; A Marthopoulos; A Chrisoulidou; K Raptou; K Tziomalos; K Pazaitou-Panayiotou
Journal:  Hippokratia       Date:  2013-07       Impact factor: 0.471

7.  Malignancy rate of thyroid nodules defined as follicular lesion of undetermined significance and atypia of undetermined significance in thyroid cytopathology and its relation with ultrasonographic features.

Authors:  Neslihan Çuhaci; Dilek Arpaci; Rıfki Üçler; Aylin Kilic Yazgan; Gülten Kıyak; Samet Yalçin; Pamir Eren Ersoy; Gülnür Güler; Reyhan Ersoy; Bekir Çakir
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

8.  Clinical characteristics and genetic screening of an extended family with MEN2A.

Authors:  E Algün; N Abaci; M Kösem; C Kotan; B Köseoğlu; H Boztepe; R Sekeroğlu; H Aslan; C Topal; H Ayakta; I Uygan; F Alagöl; N Erginel-Unaltuna; H Aksoy
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

9.  Investigation of factors potentially influencing calcitonin levels in the screening and follow-up for medullary thyroid carcinoma: a cautionary note.

Authors:  Christoph Guesgen; Arnulf Willms; Axel Zwad; Stephan Waldeck; Helmut Wieler; Robert Schwab
Journal:  BMC Clin Pathol       Date:  2013-11-04

10.  Calcitonin-secreting pancreatic neuroendocrine tumor in a patient with elevated thyroid fine-needle aspirate calcitonin washout: A case report and review of the literature.

Authors:  Darryl Mason; Robert Leimbach; Robert Kitz; Robert Vietor; Nicole Vietor
Journal:  Clin Case Rep       Date:  2022-01-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.